Dr. Christian Weisshaupt
Medizinische Onkologie und Hämatologie · Dept. I
An open-label, mulit-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug com-binations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)
Nov 16, 2022Das Ziel dieser Studie ist es herauszufinden, ob die Zuga-be der Prüfsubstanz NIS793 allein oder in Kombination mit einem Medikament namens Tislelizumab zur Standard-Krebstherapie möglicherweise Behandlungen von meta-stasiertem kolorektalem Karzinom...
Clinical Studies - Nov 16, 2022 - Mar 31, 2025
Ongoing
Project leader: Weisshaupt Christian
Members: Aeschbacher Anette
A phase II, open label, randomized, parallel arm study of
Oct 2, 2020Study of efficacy and safety of NIS793 (anti-TGFbeta antibody) with and without spartalizumab (anti-PD-1 antibody) in combination with SOC chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
Clinical Studies - Oct 2, 2020 - Aug 29, 2021
Automatically Closed
Project leader: Horber Daniel
Members: Bickel Angelika, Weisshaupt Christian
CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
Oct 21, 2016CA209577 is a phase 3, randomized, double-blind, placebo controlled study of adjuvant nivolumab in subjects with resected esophageal cancer (EC), or gastroesophageal junction (GEJ) cancer who have received chemoradiother-apy(CRT) followed by surgery....
Clinical Studies - Oct 21, 2016 - Nov 30, 2017
Automatically Closed
Project leader: Weisshaupt Christian
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
May 27, 2016Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final contact. After a screening phase of up to 42 days, eligible subjects can be randomized to either pembrolizumab (experimental...
Clinical Studies - May 27, 2016 - Nov 30, 2020
Automatically Closed
Project leader: Weisshaupt Christian
An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors
Jul 8, 2015MO29518 ist eine offene, multizentrische, multinationale Phase-II-Studie mit 10 Kohorten, welche MPDL3280A (Anti-PD-L1 Antikörper) bei Patienten mit fortgeschrittenen soliden Tumoren untersucht (Gebärmutterhalskrebs, Nasen-Rachenkrebs, spezielle Art...
Clinical Studies - Jul 8, 2015 - Jul 31, 2019
Automatically Closed
Project leader: Gillessen Sommer Silke
Members: Schmid Sabine, Fischer Stefanie, Rothermundt Christian, Templeton Arnoud, Omlin Aurelius, Desax Marie-Claire, Früh Martin, Weisshaupt Christian